Q1 kicks off with J&J, Novartis, Glaxo results

So far, 2018 has lived up to the pharmaceutical industry's expectations, delivering on the M&A front with several relatively big-ticket transactions. Big pharma investors, though, will be looking for evidence of further dealmaking and will expect companies to shed light on potential areas of interest when earnings season kicks off for the first quarter next week.